<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331747</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-05-3985-UG-CTIL</org_study_id>
    <nct_id>NCT00331747</nct_id>
  </id_info>
  <brief_title>Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate</brief_title>
  <official_title>Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple
      sclerosis (MS) patients.

      During the study patients will undergo a 3 dimensional gait analysis before starting
      treatment with glatiramer acetate and after 1 year of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will
      undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate.
      The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1
      system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped
      and will also undergo a detailed physical examination by a physical therapist.

      Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be
      observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.

      Repeat gait analysis will be performed after one year of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Computerized gait analysis: at the beginning of treatment and after 1 year</measure>
  </primary_outcome>
  <enrollment>20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of multiple sclerosis

          -  EDSS less than 5.5

          -  No cognitive disability

        Exclusion Criteria:

          -  EDSS over 5.5

          -  Inability to cooperate with gait analysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uri Givon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center; Tel Aviv University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anat Achiron, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sheba Medical Center; Tel Aviv University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uri Givon, MD</last_name>
    <phone>+972-35304451</phone>
    <email>urigi@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple Sclerosis Center, Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uri Givon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>July 5, 2006</last_update_submitted>
  <last_update_submitted_qc>July 5, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

